The effect of the surgical treatment in the complex management on life expectancy of thymic Hodgkin's lymphoma

Abstract

The result of treatment of primary Hodgkin's lymphoma lesion of the thymus gland of a 26-year-old patient is presented. At the preoperative stage of examination, “tumor maligna” cells were obtained during puncture of mediastinal formation. The diagnosis is malignant tumor of the mediastinum. Considering this, a surgical treatment was performed-radical removal of the mediastinal tumor. After the study of the postoperative drug, a clinical diagnosis was made: lymphogranulomatosis, a massive (bulky) tumor lesion of the mediastinum, stage IIХ, after surgical treatment. First course of ABVD chemotherapy was performed 28 days after the operation. When performing the second course of chemotherapy according to the same scheme, the patient developed complications in the form of moderate leukocytopenia (leukocytes, 0.9×10⁹/l) and stomatitis. Special treatment was discontinued, and the patient was observed by an oncologist in the polyclinic of an oncological dispensary.

At the next examination, which was performed 11 months later, a relapse of the disease was identified. Considering the preservation of persistent leukopenia (leukocytes, 3.0×10⁹/l), it was decided to conduct six courses of ABVD polychemotherapy with prednisone, against the background of G-CSF. At this stage of oncology, the main method of treating Hodgkin's lymphoma is chemo-hormone therapy in combination with radiation therapy. The performed non-standard complex treatment is radical surgical removal of a mediastinal tumor followed by polychemotherapy. It allowed 4 years after the completion of treatment to know motherhood, which did not affect the patient's health. As indicated by the long relapse, free period of the disease is 16 years, and life expectancy is 18 years.

Keywords

thymus / mediastinum / complex treatment / Hodgkin’s lymphoma

References

[1] Sushko AA, Prokopchik NI, Mozheyko MA, et al. Diagnostics and treatment of tumors and tumor-like formations of the mediastinum. Journal of the Grodno State Medical University. 2015;(3):51–55. (In Russ).

[2] Сушко А.А., Прокопчик Н.И., Можейко М.А., и др. Диагностика и лечение опухолей и опухолевидных образований средостения // Журнал Гродненского государственного медицинского университета 2015. № 3. С. 51–55.

[3] Lazutin YuN, Kartashov SZ, Zinkovich SA, et al. Modern approaches to treatment of patients with tumours of mediastinum. Izvestia of Samara Scientific Center of the Russian Academy of Sciences . 2009;(11(5-2):468–471. (In Russ).

[4] Лазутин Ю.Н., Карташов С.З., Зинькович С.А., и др. Современные подходы к лечению больных с опухолями средостения // Известия Самарского научного центра Российской академии наук. 2009. Т. 11, № 5-2. С. 468–471.

[5] Poteshkina NG, Troshina AA, Maslova MY, at al. Mediastinal mass in clinical practice // Medical advice. 2018;(5):104–108. (In Russ). doi: 10.21518/2079-701X-2018-5-104-108

[6] Потешкина Н.Г., Трошина А.А., Маслова М.Ю., и др. Образования средостения в клинической практике // Медицинский cовет. 2018. № 5. С. 104–108. doi: 10.21518/2079-701X-2018-5-104-108

[7] Aroor AR, Prakasha SR, Seshadri SST, Raghuraj U. A study of clinical characteristicsof mediastinal mass. J Clin Diagn Res. 2014;8(2):77–80. doi: 10.7860/JCDR/2014/7622.4013

[8] Aroor A.R., Prakasha S.R., Seshadri S.S.T., Raghuraj U. A study of clinical characteristicsof mediastinal mass // J Clin Diagn Res. 2014. Vol. 8, N 2. P. 77–80. doi: 10.7860/JCDR/2014/7622.4013

[9] Eichenauer DA, Engert A, André M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii70–iii75. doi: 10.1093/annonc/mdu181

[10] Eichenauer D.A., Engert A., André M., et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. Vol. 25, Suppl 3. P. iii70– iii75. doi: 10.1093/annonc/mdu181

[11] Mazurok LA, Kolomeitsev OA, Tumyan GS, et al. Primary mediastinal B-large cell lymphoma. Oncohematology. 2007;2(2):16–23. (In Russ).

[12] Мазурок Л.А., Коломейцев О.А., Тумян Г.С., и др. Первичная медиастинальная В-крупноклеточная лимфома // Онкогематология. 2007. Т. 2, № 2. С. 16–23.

[13] Trahtenberg AH, Pikin OV. Zlokachestvennye opuholi sredostenija. In: Chissov VI, Daryalova SL, editors. Klinicheskie rekomendacii. Onkologija 2006. Moscow; 2006. P. 246–266. (In Russ).

[14] Трахтенберг А.Х., Пикин О.В. Злокачественные опухоли средостения. В кн.: Клинические рекомендации. Онкология 2006 / под ред. В.И. Чиссова и С.Л. Дарьяловой. Москва, 2006. С. 246–266.

[15] Shavlokhov VS, Karagyulyan SR, Moiseeva TN, et al. Surgical treatment of relapsing mediastinal and pulmonary tumors in patients with Hodgkin’s disease and diffuse large B-cell lymphoma. Russian Journal of Hematology and Transfusiology. 2012;57(1):18–23 (In Russ).

[16] Шавлохов В.С., Карагюлян С.Р., Моисеева Т.Н., и др. Хирургическое лечение рецидивов опухолей средостения и лёгких у больных лимфогранулематозом и диффузной В-клеточной лимфомой // Гематология и трансфузиология. 2012. Т. 57, № 1. С. 18–23.

[17] Shalyga IF, Grishakov VV, Martemyanova LA, et al. Hodgkin’s lymphoma with extranodular manifestations. Health and Ecology Issues. 2017;2:106–110. (In Russ).

[18] Шалыга И.Ф., Гришаков В.В., Мартемьянова Л.А., и др. Лимфома Ходжкина с экстранодулярными проявлениями // Проблемы здоровья и экологии. 2017. № 2. С. 106–110.

RIGHTS & PERMISSIONS

Fokeev S.D., Lazarev A.F., Kapitulin S.Y., Kazantseva E.S., Kapitulina E.K.